Akebia Therapeutics Inc (AKBA)

May 04, 2026

Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan

May 04, 2026

May 04, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 04, 2026

May 04, 2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win - GlobeNewswire

May 04, 2026

May 02, 2026

MSN Money - MSN

May 02, 2026

May 01, 2026

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Moomoo

May 01, 2026

May 01, 2026

Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

May 01, 2026

May 01, 2026

AKBA Forecast, Price Target & Analyst Ratings | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill

May 01, 2026

May 01, 2026

Earnings Preview: AKBA to Report Financial Results Pre-market on May 07 - Moomoo

May 01, 2026

Apr 30, 2026

Are options traders betting on a big move in Akebia Therapeutics stock? - MSN

Apr 30, 2026

Apr 28, 2026

Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan

Apr 28, 2026

Apr 24, 2026

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Apr 23, 2026

Apr 23, 2026

Akebia (AKBA) Road Ahead | Q4 2025: EPS Misses ViewsCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 20, 2026

Akebia (AKBA) Stock: Long-Term Outlook Review (Steady Climb) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Apr 18, 2026

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 - GuruFocus

Apr 18, 2026

Apr 18, 2026

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Apr 18, 2026

Apr 17, 2026

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Potential Upside of 225.93% Draws Investor Attention - DirectorsTalk Interviews

Apr 17, 2026

Apr 16, 2026

AKBA Should I Buy - Intellectia AI

Apr 16, 2026

Apr 15, 2026

Akebia Therapeutics (NASDAQ: AKBA) asks shareholders to increase authorized stock - Stock Titan

Apr 15, 2026

Apr 15, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 15, 2026

Apr 14, 2026

Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 14, 2026

Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Sahm

Apr 14, 2026

Apr 13, 2026

Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus

Apr 13, 2026

Apr 13, 2026

Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada

Apr 13, 2026

Apr 13, 2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times

Apr 13, 2026

Apr 13, 2026

Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan

Apr 13, 2026

Apr 13, 2026

Profit Review: Is Akebia Therapeutics Inc attractive for institutional investorsGDP Growth & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - ADVFN

Apr 12, 2026

Apr 09, 2026

Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research - MarketBeat

Apr 09, 2026

Apr 08, 2026

Sectors Review: Is Akebia Therapeutics Inc stock trending bullishWeekly Risk Report & Detailed Earnings Play Strategies - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

Block Trades: What is the next catalyst for Akebia Therapeutics IncQuarterly Profit Review & Consistent Growth Stock Picks - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - marketscreener.com

Apr 07, 2026

Apr 07, 2026

BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB - GuruFocus

Apr 07, 2026

Apr 07, 2026

BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat

Apr 07, 2026

Apr 07, 2026

Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan

Apr 07, 2026

Apr 07, 2026

H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA) - The Globe and Mail

Apr 07, 2026

Apr 07, 2026

Sell Signal: Does Akebia Therapeutics Inc offer margin of safetyMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Apr 06, 2026

Apr 06, 2026

Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK

Apr 06, 2026

Apr 06, 2026

H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 06, 2026

Apr 06, 2026

How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance

Apr 06, 2026

Apr 05, 2026

Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Apr 05, 2026